Promising drug trial launches for rare cancer that spreads

NCT ID NCT06891560

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tests a drug called enfortumab vedotin in people with adenoid cystic carcinoma (ACC), a rare cancer that has come back or spread. The goal is to see if the drug can shrink tumors or slow the disease. About 34 adults will take part, and researchers will monitor side effects and how long the cancer stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOID CYSTIC CARCINOMA

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (All Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (All Protocol Activities)
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITING

East White Plains, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.